Multiple Gestation Study

NCT ID: NCT02278536

Last Updated: 2019-08-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

354 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-03-31

Study Completion Date

2019-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of the clinical study are to demonstrate the accuracy of our new NATUS diagnostic method to determine the genetic health of the developing fetuses in a multiple gestation pregnancy from a maternal blood sample. The long term goal of this study will be the development of a method of minimally invasive prenatal diagnosis that has a higher sensitivity and lower false positive rate in the intended population (e.g. multiple gestation pregnancies) than any currently available screening tests. This will result in fewer unnecessary amniocenteses and CVS procedures, which are associated with a risk of miscarriage.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Trisomy 13 Trisomy 18 Trisomy 21 Sex Chromosome Abnormalities

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Multiple high risk gestation pregnancies

women pregnant with twins or triplets at high risk for aneuploidy

No interventions assigned to this group

Multiple low risk gestation pregnancies

women pregnant with twins or triplets at low risk for aneuploidy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 or older at enrollment
* Clinically confirmed multiple gestation pregnancy
* Gestational age between ≥ 9 weeks, 0 days and ≤26 weeks 0 days by best obstetrical estimate
* Able to provide informed consent

Exclusion Criteria

* Women carrying singleton pregnancy
* Surrogate or egg donor used
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Houston Perinatal Associates

UNKNOWN

Sponsor Role collaborator

Lyndhurst Clinical Research

UNKNOWN

Sponsor Role collaborator

Dr. Carpenter Maternal Fetal Medicine Clinic

UNKNOWN

Sponsor Role collaborator

San Diego Perinatal Center

UNKNOWN

Sponsor Role collaborator

Natera, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Brian Kirshon, MD

Role: PRINCIPAL_INVESTIGATOR

Houston Perinatal Associates

Robert Lamar Parker, MD

Role: PRINCIPAL_INVESTIGATOR

Lyndhurst Clinical Research

Robert Carpenter, MD

Role: PRINCIPAL_INVESTIGATOR

Office of Dr. Robert Carpenter

Zach Demko, PhD

Role: PRINCIPAL_INVESTIGATOR

Natera, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Natera, Inc.

San Carlos, California, United States

Site Status

San Diego Perinatal Center

San Diego, California, United States

Site Status

Carnegie Hill Imaging for Women

New York, New York, United States

Site Status

Lyndhurst Clinical Research

Winston-Salem, North Carolina, United States

Site Status

Office of Dr. Robert Carpenter

Houston, Texas, United States

Site Status

Houston Perinatal Associates

Houston, Texas, United States

Site Status

Bangalore Fetal Medicine Centre

Bangalore, , India

Site Status

Fetal Medicine & Gynaecology Centre

Petaling Jaya, Selangor, Malaysia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States India Malaysia

References

Explore related publications, articles, or registry entries linked to this study.

Pergament E, Cuckle H, Zimmermann B, Banjevic M, Sigurjonsson S, Ryan A, Hall MP, Dodd M, Lacroute P, Stosic M, Chopra N, Hunkapiller N, Prosen DE, McAdoo S, Demko Z, Siddiqui A, Hill M, Rabinowitz M. Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol. 2014 Aug;124(2 Pt 1):210-218. doi: 10.1097/AOG.0000000000000363.

Reference Type BACKGROUND
PMID: 25004354 (View on PubMed)

Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, Tim R, Lu V, McCullough R, McCarthy E, Nygren AO, Dean J, Tang L, Hutchison D, Lu T, Wang H, Angkachatchai V, Oeth P, Cantor CR, Bombard A, van den Boom D. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol. 2011 Mar;204(3):205.e1-11. doi: 10.1016/j.ajog.2010.12.060. Epub 2011 Feb 18.

Reference Type BACKGROUND
PMID: 21310373 (View on PubMed)

Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Deciu C, Grody WW, Nelson SF, Canick JA. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med. 2011 Nov;13(11):913-20. doi: 10.1097/GIM.0b013e3182368a0e.

Reference Type BACKGROUND
PMID: 22005709 (View on PubMed)

Sehnert AJ, Rhees B, Comstock D, de Feo E, Heilek G, Burke J, Rava RP. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clin Chem. 2011 Jul;57(7):1042-9. doi: 10.1373/clinchem.2011.165910. Epub 2011 Apr 25.

Reference Type BACKGROUND
PMID: 21519036 (View on PubMed)

Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP; MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol. 2012 May;119(5):890-901. doi: 10.1097/AOG.0b013e31824fb482.

Reference Type BACKGROUND
PMID: 22362253 (View on PubMed)

Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Grody WW, Nelson SF, Canick JA. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med. 2012 Mar;14(3):296-305. doi: 10.1038/gim.2011.73. Epub 2012 Feb 2.

Reference Type BACKGROUND
PMID: 22281937 (View on PubMed)

Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, Caughey AB, Rodriguez MH, Williams J 3rd, Mitchell ME, Adair CD, Lee H, Jacobsson B, Tomlinson MW, Oepkes D, Hollemon D, Sparks AB, Oliphant A, Song K. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012 Aug;207(2):137.e1-8. doi: 10.1016/j.ajog.2012.05.021. Epub 2012 Jun 1.

Reference Type BACKGROUND
PMID: 22742782 (View on PubMed)

Canick JA, Kloza EM, Lambert-Messerlian GM, Haddow JE, Ehrich M, van den Boom D, Bombard AT, Deciu C, Palomaki GE. DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations. Prenat Diagn. 2012 Aug;32(8):730-4. doi: 10.1002/pd.3892. Epub 2012 May 14.

Reference Type BACKGROUND
PMID: 22585317 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

13-016-NPT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.